Comparative Pharmacology
Head-to-head clinical analysis: METHYCLOTHIAZIDE AND DESERPIDINE versus SERPANRAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYCLOTHIAZIDE AND DESERPIDINE versus SERPANRAY.
METHYCLOTHIAZIDE AND DESERPIDINE vs SERPANRAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.
None Documented
None Documented
Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing.
Terminal elimination half-life is approximately 62 hours following oral administration, allowing for once-daily dosing.
Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%).
Primarily hepatic metabolism via CYP1A2 and CYP3A4, with 18% excreted unchanged in urine and 26% in feces as metabolites.
Category C
Category C
Thiazide Diuretic and Antihypertensive
Antihypertensive